These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 22259987)
1. [The change of serum vascular endothelial growth factor and matrix metalloproteinases-9 in proliferative hemangioma treated with propranolol]. Zhao ZF; Lü RR; Huo R; Fu HB; Xu GQ Zhonghua Zheng Xing Wai Ke Za Zhi; 2011 Sep; 27(5):359-61. PubMed ID: 22259987 [TBL] [Abstract][Full Text] [Related]
2. [Effect of propranolol gel on plasma VEGF, bFGF and MMP-9 in proliferating infantile hemangiomas of superficial type]. Yujuan T; Shaoquan C; Zaizhong Z; Shuming C; Guoliang H; Lie W Zhonghua Zheng Xing Wai Ke Za Zhi; 2015 Jul; 31(4):268-73. PubMed ID: 26665926 [TBL] [Abstract][Full Text] [Related]
3. Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy. Chen XD; Ma G; Huang JL; Chen H; Jin YB; Ye XX; Hu XJ; Lin XX Pediatr Dermatol; 2013; 30(5):549-53. PubMed ID: 23909679 [TBL] [Abstract][Full Text] [Related]
4. Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients. Yuan WL; Jin ZL; Wei JJ; Liu ZY; Xue L; Wang XK Br J Oral Maxillofac Surg; 2013 Oct; 51(7):656-61. PubMed ID: 23291092 [TBL] [Abstract][Full Text] [Related]
5. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Tamura M; Oda M; Matsumoto I; Tsunezuka Y; Kawakami K; Ohta Y; Watanabe G Ann Surg Oncol; 2004 Oct; 11(10):928-33. PubMed ID: 15383417 [TBL] [Abstract][Full Text] [Related]
6. Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes. Park M; Jung HL; Shim YJ; Kim HS; Yoon HS; Park SK; Cheuh HW; Lee MJ; Lee JM; Park ES; Lee JH; Lim YJ; Choi YB Pediatr Res; 2020 Nov; 88(5):749-755. PubMed ID: 32311699 [TBL] [Abstract][Full Text] [Related]
8. Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals. Randeva HS; Lewandowski KC; Komorowski J; Murray RD; O'Callaghan CJ; Hillhouse EW; Stepien H; Shalet SM Circulation; 2004 May; 109(20):2405-10. PubMed ID: 15123527 [TBL] [Abstract][Full Text] [Related]
9. [The determination and significance of VEGF in the serum of hemangioma patients]. Hu Q; Lin X; Shang Q; Dong J; Qi Z; Wang W Zhonghua Zheng Xing Wai Ke Za Zhi; 2002 Mar; 18(2):98-100. PubMed ID: 12192772 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma. Aydin Köker S; Kömüroğlu AU; Köksoy AY; Şiraz ÜG; Tekin E; Köker A Arch Pediatr; 2021 May; 28(4):296-300. PubMed ID: 33715934 [TBL] [Abstract][Full Text] [Related]
11. Soluble receptors for vascular endothelial growth factor (sVEGFR1/sVEGFR2) in infantile hemangioma. Przewratil P; Sitkiewicz A; Andrzejewska E Growth Factors; 2010 Dec; 28(6):417-25. PubMed ID: 20854187 [TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas? Babiak-Choroszczak L; Giżewska-Kacprzak K; Gawrych E; Fischer K; Walecka A; Puchalska-Niedbał L; Rajewska-Majchrzak J; Bagłaj M Adv Clin Exp Med; 2018 May; 27(5):703-710. PubMed ID: 29790692 [TBL] [Abstract][Full Text] [Related]
13. Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor. Ozeki M; Nozawa A; Hori T; Kanda K; Kimura T; Kawamoto N; Fukao T Pediatr Int; 2016 Nov; 58(11):1130-1135. PubMed ID: 26991797 [TBL] [Abstract][Full Text] [Related]
14. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs. Gentilini F; Calzolari C; Turba ME; Agnoli C; Fava D; Forni M; Bergamini PF Leuk Res; 2005 Nov; 29(11):1263-9. PubMed ID: 15893373 [TBL] [Abstract][Full Text] [Related]
16. The correlation between resting serum leptin and serum angiogenic indices at rest and after submaximal exercise. Nourshahi M; Hedayati M; Ranjbar K Regul Pept; 2012 Jan; 173(1-3):6-12. PubMed ID: 21924298 [TBL] [Abstract][Full Text] [Related]
17. [Expression of serum and urinary vascular endothelial growth factor-A and epidermal growth factor-like domain 7 in proliferating hemangioma treated with propranolol]. Bin L; Manli C; Jie L; Xiaopeng Y; Zhaoquan L; Zhongcheng G Hua Xi Kou Qiang Yi Xue Za Zhi; 2014 Oct; 32(5):441-5. PubMed ID: 25490818 [TBL] [Abstract][Full Text] [Related]
18. Role of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, and Vascular Endothelial Growth Factor in the Development of Chronic Subdural Hematoma. Hua C; Zhao G; Feng Y; Yuan H; Song H; Bie L J Neurotrauma; 2016 Jan; 33(1):65-70. PubMed ID: 25646653 [TBL] [Abstract][Full Text] [Related]
19. IGF-1, IGFBP-3, VEGF and MMP-9 levels and their potential relationship with renal functions in patients with compensatory renal growth. Yildiz B; Kural N; Colak O; Ak I; Akcar N Clin Physiol Funct Imaging; 2008 Mar; 28(2):107-12. PubMed ID: 18093232 [TBL] [Abstract][Full Text] [Related]
20. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin]. Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]